Values First Advisors’s Trillium Therapeutics TRIL Stock Holding History
Bought
Maintained
Sold
Other funds holding TRIL
Values First Advisors's TRIL Position: Q4 2021 in Review
Values First Advisors sold out of Trillium Therapeutics (TRIL) in Q4 2021, closing a stake of 25,768 shares — an estimated $452K sold.
Values First Advisors first reported a position in TRIL in Q1 2021 and held it in 3 quarters. The position peaked at $452K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.
- Values First Advisors reported no remaining Trillium Therapeutics position as of Q4 2021 after selling out during the quarter.
- Values First Advisors sold 25,768 Trillium Therapeutics shares in Q4 2021, an estimated $452K.
- Values First Advisors first reported a position in Trillium Therapeutics in Q1 2021 and held it in 3 quarters.
- Values First Advisors's Trillium Therapeutics position peaked at $452K in Q3 2021.
- 2 funds tracked by Wall St. Rank held Trillium Therapeutics as of Q4 2021.
Based on Values First Advisors's 13F filing for Q4 2021, filed 10 Mar 2022.